Compare AbbVie Inc (ABBV) vs Nerdwallet Inc (NRDS) Price & Performance

AbbVie IncTrade

Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Nerdwallet Inc — how do they compare? AbbVie Inc trades at $249.84 (market cap $441.94B), while Nerdwallet Inc trades at $9.78 (market cap $625.17M). The key difference: AbbVie Inc is far larger — about 706.9× Nerdwallet Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

	ABBV	NRDS
Market Cap	$441.94B	$625.17M
Sector	Health	Financials
52-Week High	$263.58	$15.93
52-Week Low	$197.38	$7.58
Enterprise Value	$506.19B	$539.47M
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Nerdwallet Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 22 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

NRDS

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.